ACS OV: An alternative to well established tests also measuring CA 125?;ACS OV: Eine Alternative zu etablierten Tests fur die Messung von CA 125?

Clinical Laboratory

Volumn 43, Issue 6, 1997, Pages 515-526

  Roth, H J ^a,b   Zahn, I ^a  

^a Laboratory Group   (Germany)

^b Abt Mikrobiologie   (Germany)

Author keywords

ACS OV; ACS:180 Plus; Assay comparison; CA 125; HAMA

Indexed keywords

ANTIBODY; CA 125 ANTIGEN; TUMOR MARKER;

ANTIBODY TITER; ARTICLE; AUTOANALYSIS; BLOOD LEVEL; CHEMOLUMINESCENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; HISTOGRAM; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; OVARY CANCER; PATIENT MONITORING; REFERENCE VALUE;

EID: 0030930734     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Parker SL, Tong T, Bolden S, et al. Cancer statistics, 1996. CaA Cancer Journal for Clinicians 1996;46(1):5-27.
2. Whittemore AS, Wu ML, Paffenbarger RS, et al. Personal and environmental characteristics related to epithelial ovarian cancer: II. Exposures to talcum powder, tobacco, alcohol and coffee. Am J Epidemiology 1988; 128(6):1228-1240.
3. Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case control studies: II. Invasive epithelial ovarian cancers in white women: Collaborative Ovarian Cancer Group. Am J Epidemiology 1992; 136(10): 1184-1203.
4. Cramer DW, Hutchinson GB, Welch WR, et al. Determinants of ovarian cancer risk: I. Reproductive experiences and family history. J Nat C Inst 1983; 71(4):711-716.
5. Bast RC Jr, Freeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981; 68:1331-1337.
6. Bast RC Jr, Klug TL, St John E, et al. A radioimmunoassay using monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983; 309:883-887.
7. Nouwen EJ, Hendrix PG, Dauwe S, Eerdekens MW, De Broe ME. Tumour markers in the human ovary and its neoplasms. A comparative immunohistochemical study. Am J Pathol 1987; 126:230-242.
8. Zrawski VR Jr, Davis HM, Finkler NJ, Harrison CL, Bast RC Jr, Knapp RC. Tissue distribution and characteristics of CA 125 antigen. Cancer Rev 1988; 11/12:102-118.
9. Kuzuya K, Nozaki M, Chihara T. Evaluation of CA 125 as a circulation tumour marker for ovarian cancer. Nippon Sanka Fujinka Gakkai Zasshi 1986; 38:949-957.
10. Kenemans P, Yedema CA, Bon GG, von Mensdorff-Pouilly S. CA 125 in gynaecological pathology - a review. Eur J Obstet Gynecol Reprod Biol 1993; 49:115-124.
11. Nustad K et al. Specificity and affinity of 26 monoclonal antibodies against the CA 125 antigen: First Report from the ISOBM TD-1 Workshop. Tumour Biol 1996;17:196-219.
12. Muto MG, Lepisto EM, Van den Abbeele AD, Knapp RC, Kassis AI. Influence of human antimurine antibody on CA 125 levels in patients with ovarian cancer undergoing radioimmunotherapy or immunoscintigraphy with murine monoclonal antibody OC 125. Am J Obstet Gynecol 1988; 161(5)1206-1212.
13. Boscato LM, Stuart MC. Heterophilic antibodies: a problem for all immunoassays. Clin Chem 1988; 34:27-33.
14. Price T, Beatty BG, Baetty JD, McNally AJ. Human anti-murine antibody interference in measurement of carcinoembryonic antigen assessed with a double-antibody enzyme immunoassay. Clin Chem 1991; 37(1):51-57.
15. Turpeinen U, Lehtovirta P, Stenman UH. CA 125 determined by three methods in samples from patients with human anti-mouse antibodies (HAMA). Clin Chem 1995; 41:1667-1669.
16. Kricka LJ, Schmerfeld-Pruss D, Senior M, Goodmann DBP, Kaladas P. Interference by human anti-mouse antibody in two-site immunoassays. Clin Chem 1990; 36:892-894.
17. Boerman OC, Segers MFG, Poels LG, Kenemans P, Thomas CMG. Heterophilic antibodies in human sera causing falsely increased results in the CA 125 immunofluorometric assay. Clin Chem 1990;36:888-891.
18. Moessner E, Lenz H, Bienhaus G. Elimination of heterophilic antibody interference in monoclonal sandwich tests. Clin Chem 1990. 36: 1092 No 6 Abstr-No 0659.
19. 2fragments of the OC125 antibody. Eur J Clin Chem Clin Biochem 1993; 31:323-327.
20. 2 fragments of OC125 antibody. Clin Chem 1993; 39(5):891-896.
21. Reinsberg J, Richter H. Determination of the cancer antigen 125 with a second generation assay - interferences by human antiOC125 antibodies. Clin Lab 1995; 41:345-350.
22. Klenner D, Uhl W. Eine Streptavidin-Universalfestphase führt zu einer neuen Generation von Tumour Marker Testen. Lab Med 1991; 9:323-330.
23. Thomas CMG, Massuger LFAG, Segers MFG, Schijf CPT, Doesburg WH, Wobbes T. Analytical and clinical performance of improved Abbott IMx CA 125 Assay: Comparison with Abbott CA 125 RIA. Clin Chem 1995;41:211-216.
24. Roth HJ. Automation in the immunoassay laboratory.Clin Lab 1993; 39:108-112.
25. Pollock MA, Jefferson SG, Kane JW, Lomax K, MacKinnon G, Winnard CB. Method comparison - a different approach. Ann Clin Biochem 1992; 29:556-560.
26. Van Kamp GJ, Verstraeten AA, Kenemans P. Discordant serum CA 125 values in commercial immunoassays. Eur J Obstet Gynecol Reprod Biol 1993; 49:99-103.
27. Hashimoto T, Ohba N, Matsubara F. Discordant CA 125 measurements in normal healthy women. Clin Chem 1990;36(7):1377-1378.